Gencurix Inc. (KOSDAQ:229000)

South Korea · Delayed Price · Currency is KRW

2,190.00

+125.00 (6.05%)

Jun 29, 2026, 3:30 PM KST

-7.01% (1Y)

Market Cap	51.31B +92.5%
Revenue (ttm)	3.39B +25.7%
Net Income	-12.55B
EPS	-877.76
Shares Out	23.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2,190.00
Previous Close	2,065.00
Day's Range	2,190.00 - 2,190.00
52-Week Range	1,385.00 - 7,320.00
Beta	1.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo... [Read more]

Industry Medical - Specialties

Sector Healthcare

Founded 2011

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 229000

Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements